139 related articles for article (PubMed ID: 12699361)
21. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.
Karlsson Hedestam GB; Fouchier RA; Phogat S; Burton DR; Sodroski J; Wyatt RT
Nat Rev Microbiol; 2008 Feb; 6(2):143-55. PubMed ID: 18197170
[TBL] [Abstract][Full Text] [Related]
22. Epitope-vaccine strategy against HIV-1: today and tomorrow.
Liu Z; Xiao Y; Chen YH
Immunobiology; 2003; 208(4):423-8. PubMed ID: 14748515
[TBL] [Abstract][Full Text] [Related]
23. Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides.
Belliard G; Hurtrel B; Moreau E; Lafont BA; Monceaux V; Roques B; Desgranges C; Aubertin AM; Le Grand R; Muller S
Vaccine; 2005 Feb; 23(11):1399-407. PubMed ID: 15661389
[TBL] [Abstract][Full Text] [Related]
24. Toward an antibody-based HIV-1 vaccine.
Hoxie JA
Annu Rev Med; 2010; 61():135-52. PubMed ID: 19824826
[TBL] [Abstract][Full Text] [Related]
25. Tat toxoid: its potential role as an HIV vaccine.
Lambert J
J Hum Virol; 1998; 1(4):249-50. PubMed ID: 10195248
[No Abstract] [Full Text] [Related]
26. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials.
Ensoli B; Fiorelli V; Ensoli F; Cafaro A; Titti F; Buttò S; Monini P; Magnani M; Caputo A; Garaci E
AIDS; 2006 Nov; 20(18):2245-61. PubMed ID: 17117011
[No Abstract] [Full Text] [Related]
27. HIV-1 Tat protein as a potential AIDS vaccine.
Goldstein G
Nat Med; 1996 Sep; 2(9):960-4. PubMed ID: 8782444
[No Abstract] [Full Text] [Related]
28. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.
Calarota SA; Kjerrström A; Islam KB; Wahren B
Hum Gene Ther; 2001 Sep; 12(13):1623-37. PubMed ID: 11535166
[TBL] [Abstract][Full Text] [Related]
29. GP120: target for neutralizing HIV-1 antibodies.
Pantophlet R; Burton DR
Annu Rev Immunol; 2006; 24():739-69. PubMed ID: 16551265
[TBL] [Abstract][Full Text] [Related]
30. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?
Sekaly RP
J Exp Med; 2008 Jan; 205(1):7-12. PubMed ID: 18195078
[TBL] [Abstract][Full Text] [Related]
31. Peptide immunogens based on the envelope region of HIV-1 are recognized by HIV/AIDS patient polyclonal antibodies and induce strong humoral immune responses in mice and rabbits.
Hewer R; Meyer D
Mol Immunol; 2003 Oct; 40(6):327-35. PubMed ID: 14522014
[TBL] [Abstract][Full Text] [Related]
32. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
[TBL] [Abstract][Full Text] [Related]
33. Developing broadly reactive HIV-1/AIDS vaccines: a review of polyvalent and centralized HIV-1 vaccines.
McBurney SP; Ross TM
Curr Pharm Des; 2007; 13(19):1957-64. PubMed ID: 17627529
[TBL] [Abstract][Full Text] [Related]
34. Human immunodeficiency virus antibodies and the vaccine problem.
Chiodi F; Weiss RA
J Intern Med; 2014 May; 275(5):444-55. PubMed ID: 24581142
[TBL] [Abstract][Full Text] [Related]
35. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
36. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
Wright PF; Mestecky J; McElrath MJ; Keefer MC; Gorse GJ; Goepfert PA; Moldoveanu Z; Schwartz D; Spearman PW; El Habib R; Spring MD; Zhu Y; Smith C; Flores J; Weinhold KJ;
J Infect Dis; 2004 Apr; 189(7):1221-31. PubMed ID: 15031791
[TBL] [Abstract][Full Text] [Related]
37. Development of an epitope-based HIV-1 vaccine strategy from HIV-1 lipopeptide to dendritic-based vaccines.
Surenaud M; Lacabaratz C; Zurawski G; Lévy Y; Lelièvre JD
Expert Rev Vaccines; 2017 Oct; 16(10):955-972. PubMed ID: 28879788
[TBL] [Abstract][Full Text] [Related]
38. A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A-C subtypes and the ancestor sequence of the F-H subtypes. Preclinical and clinical studies.
Krohn K; Stanescu I; Blazevic V; Vesikari T; Ranki A; Ustav M
Microbes Infect; 2005 Nov; 7(14):1405-13. PubMed ID: 16257560
[TBL] [Abstract][Full Text] [Related]
39. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.
Borsutzky S; Fiorelli V; Ebensen T; Tripiciano A; Rharbaoui F; Scoglio A; Link C; Nappi F; Morr M; Buttó S; Cafaro A; Mühlradt PF; Ensoli B; Guzmán CA
Eur J Immunol; 2003 Jun; 33(6):1548-56. PubMed ID: 12778472
[TBL] [Abstract][Full Text] [Related]
40. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
van Gils MJ; Sanders RW
Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
